Viral vector demand still exceeds capacity, according to analysts who say biopharma firms and CDMOs need new facilities and more efficient production processes. Industry concerns about vector supplies ...
MALVERN, Pa.--(BUSINESS WIRE)--Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing ...
1. Theoretical models suggest that increased vector species participation in pathogen transmission significantly increases the prevalence of vector and host infections. However, there has been a lack ...
Vibalogics began the first stage of a planned $50 million dollar investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical virotherapy manufacturing capacity. The investment ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
CHARLEROI, Belgium, March 23, 2022 /PRNewswire/ -- Exothera S.A., a CDMO specialized in the development and manufacture of viral vectors for vaccines and gene therapies, received Good Manufacturing ...
Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback